Echocardiography image is courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
Having access to LUMASON, which does not require special equipment, has allowed us to continue to utilize contrast when needed without additional equipment or staff that would otherwise bring an activated vial into an isolation room.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Having the convenience of everything I need in a single kit to administer quickly means I can spend more time focusing on the patient.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
I never realized how much time I spent getting the refrigerated agent from storage, finding the mixer and reconstituting – I guess we never knew we had other options?
Very low MI techniques produce high quality signal-to-noise ratios giving you the ability to be visually decisive.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Echocardiography images are courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
Learning to recognize your segments in 4-chamber, 2-chamber and 3-chamber apical views quickly is the foundation for becoming a Great Sonographer.
Echocardiography images are courtesy of Dr. Linda Gillam, Atlantic Health System, Morristown, NJ. Individual results may vary.
Patient’s experiencing back pain doesn’t just increase the time it takes to complete the study, it impacts patient satisfaction.
The individual who appears is for illustrative purposes. The person depicted is a model and not a real patient.
* Based on a single-center study of adult patients (age >18 years) receiving a UEA (LUMASON®, Optison™, or Definity®) were prospectively evaluated for clinically significant adverse events defined as either anaphylactoid reactions (rash, flank pain, dyspnea, and wheeze) or true anaphylaxis. Study objectives included the following: determining the major adverse reactions experienced by patients receiving UEA in a clinical setting, assessing whether microbubbles are safe for use in patients with intra-cardiac shunts, and assessing whether the types of adverse reactions differ significantly among the three FDA-approved UEAs.
There’s only one agent we trust for our pediatric patients.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real patients or healthcare professionals.
Dr. Stephanie Wilson
LUMASON is the only UEA approved for pediatric patients.3
There’s only one agent we trust for our pediatric patients.
The individual who appears is for illustrative purposes. The person depicted is a model and not a real patient.
We are looking for a large number of biomedical applications, and are confident that our technology can be used to address a wide range of healthcare challenges, for the best of patient care.
The Geneva Center, Bracco Research SA.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real healthcare professionals.
This program was great and I don’t think that there is anything like this anywhere else. Very good classes and not the standard canned presentations that we are accustomed to seeing.
I would encourage all sonographers to participate in this program if given the opportunity to. This is coming from a sonographer that has 20 years of experience and injected over 5000 doses of ultrasound enhancing agents.
The physics, chemistry and explanation of ultrasound enhancing agents were second to none. The interactive nature of the class was great and probably the most important part of the program. You don’t usually get to be this close to people that are the gurus of any specialty. The actual lab portion was invaluable and is the highlight of the course.
The individuals who appear are for illustrative purposes. All persons depicted are models and not real healthcare professionals.
LUMASON® is an ultrasound contrast agent indicated for use:
LUMASON® is contraindicated in patients with:
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of LUMASON [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].3
Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).
LUMASON and SONOVUE are registered trademarks of Bracco Diagnostics Inc. and its affiliated entities.
All other trademarks and registered trademarks are the property of their respective owners.
© 2020 Bracco Diagnostics Inc. All Rights Reserved.